SCHEMBL4515713

SCHEMBL4515713

CC(CCc1nc2c(ncn2C)c(=O)n1-c1ccc(Cl)cc1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.39
DRD5 P21918 2/20 0.39
TSHR P16473 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
PDE10A Q9Y233 2/20 0.34
LMNA P02545 1/20 0.34
XBP1 P17861 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAOB P27338 4/20 0.33
MAOA P21397 3/20 0.33
CNR1 P21554 1/20 0.33
NPC1 O15118 1/20 0.32
MAT2A P31153 1/20 0.32
POLB P06746 1/20 0.32
HKDC1 Q2TB90 1/20 0.32
GRM1 Q13255 1/20 0.32
ALDH1A3 P47895 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977073 1.00 DRD1 (0.39) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4288347 1.00 DRD1 (0.39) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4520603 0.94 DRD1 (0.38) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4521064 0.91 HKDC1 (0.40) TSHRALDH1A1PDE10ALMNAMAOB
SCHEMBL4978894 0.90 DRD1 (0.44) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4427544 0.90 DRD1 (0.44) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4427546 0.90 DRD1 (0.44) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4521631 0.89 TSHR (0.37) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4530214 0.88 DRD1 (0.44) DRD1DRD5TSHRALDH1A1KDM4E
SCHEMBL4519841 0.87 CNR1 (0.43) DRD1DRD5TSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 DRD1 1261/4885DRD5 1056/4885TSHR 119/4885
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 DRD1 333/4885DRD5 695/4885TSHR 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.